<DOC>
	<DOCNO>NCT01730638</DOCNO>
	<brief_summary>The aim study optimize pretargeting parameter use pharmacokinetic image data immuno-PET use anti-CEA x anti-HSG TF2 BsMAb 150 MBq 68Ga-IMP-288 peptide MTC patient abnormal Ct serum level initial complete surgery least one abnormal lesion</brief_summary>
	<brief_title>ImmunoTEP Patients With Medullary Thyroid Carcinoma .</brief_title>
	<detailed_description>Variation TF2 molar dose , IMP-288 molar dose pretargeting interval perform 4 5 cohort 3 patient , receive 30 120 nmol TF2 1.5 6 nmol peptide 1 3 day apart . Blood sample obtain TF2 68Ga-IMP-288 injection . A last cohort ( cohorte number 5 6 ) optimal condition propose . Whole-body PET image record 60 120 minute 68Ga-IMP-288 injection ass semi-quantitatively tumor target tumor/background ratio . Moreover , target sensitivity TF2-pretargeted 68Ga-IMP-288 compare standard method tumor . patient second immuno-TEP follow first examen sensible .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Thyroid Diseases</mesh_term>
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Neuroendocrine</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Histological diagnosis CMT Calcitonin &gt; 150 pg / ml Complete treatment primary tumor least one detectable lesion 10 mm conventional imaging : bone lesion take account extend outside bone party extra bone measurable . Age ≥ 18 year Negative pregnancy test woman childbearing age previous 2 day immunoPET . Women childbearing potential use effective contraception take continuously 3 month . KPS ≥ 70 ECOG 01 life expectancy least 6 month Absence serious illness comorbidity assess risk Creatinine ≤ 2.5 normal Absence cancer treatment within 6 week prior immunoPET No history cancer within 5 year , except skin cancer melanoma carcinoma situ cervix Lack antiantibodies patient previously receive antibody hypersensitivity antibody protein Informed consent sign Social Insurance Pregnancy breastfeed Serious illness comorbidity assess risk History cancer within 5 year , except skin cancer melanoma carcinoma situ cervix Presence antiantibodies patient previously receive antibody Known hypersensitivity antibody protein Need establish cancer treatment within 3 month immunoPET ( stock evaluation 3 month ) Inability intellectual sign consent Patient protect law</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>thyroid ,</keyword>
	<keyword>endocrine tumour</keyword>
	<keyword>Nuclear medicine ,</keyword>
	<keyword>molecular imaging</keyword>
	<keyword>ImmunoTEP</keyword>
</DOC>